ZURICH/ LONDON, Oct 22 – Roche sales rose in the third quarter, the Swiss drugmaker said on Thursday, slightly beating analyst expectations.
With growth in both its pharmaceuticals and diagnostics divisions, group sales came in at 16.13 billion Swiss francs ($19.61 billion), slightly above average analyst expectations of 15.75 billion Swiss francs in a company compiled consensus.
(Reporting by Patrick Wingrove and Marleen KaesebierEditing by Linda Pasquini)
Comments